The Patient Care America settlement is a practical False Claims Act diligence case for PE-backed healthcare platforms: marketing economics, commission payments, and investor approvals can become central when claims are allegedly generated through kickbacks. This case study walks through the alleged mechanism, the diligence tests it implies, how to read the primary source document, and how a buyer or investor should structure the workstream before signing or wiring.
By Noah Green CPA CFE
This article is for general diligence education. It is not legal advice, investment advice, tax advice, or a conclusion about any specific transaction. DOJ alleged misconduct, and the matter resolved by settlement, not a liability finding. Verify current public sources and any follow-on posture before publication.
The Short Version
DOJ announced on September 18, 2019 that Patient Care America, two of its executives, and private equity firm Riordan, Lewis and Haden agreed to pay \$21.36 million to resolve False Claims Act allegations. DOJ alleged that kickbacks generated prescriptions for expensive compounded creams and vitamins regardless of patient need, and that RLH managed PCA and funded the commission payments that allegedly drove that referral volume.
For buyers and investors, the core lesson is narrow and specific: when a sponsor’s approvals, budget decisions, board materials, or funding flows touch the mechanism that generates federally reimbursed claims, the sponsor is not safely outside the compliance fact pattern. The corporate structure does not create automatic distance if the economic facts connect the investor to the alleged conduct.
The case is also a reminder that FCA exposure does not require a trial or a liability finding to be material. A \$21.36 million settlement across a pharmacy, two executives, and a PE firm is a concrete reference point for what referral-economics risk can cost when it surfaces in a federal program billing context.
For the broader checklist, see the private equity healthcare rollup diligence guide and the Aspen DSO clinical-control case study in this series.
Public Posture
The settlement was announced September 18, 2019. The DOJ press release describes a compounding pharmacy platform serving TRICARE beneficiaries. The public record states that the settlement totaled \$21.36 million and involved the pharmacy, two executives, and the private equity firm.
The publication-safe framing matters here. DOJ alleged a PE firm and its portfolio pharmacy participated in a kickback-driven prescription scheme. The matter resolved by settlement. There was no trial, no jury verdict, and no judicial finding of liability. The settlement is a public fact. The underlying conduct is alleged conduct. Both points belong in any article, memo, or diligence report that cites this case.
The case originated as a qui tam action, meaning a relator filed under the False Claims Act’s whistleblower provisions before DOJ intervened. That procedural posture is itself a diligence signal: FCA whistleblower cases can sit under seal for years before a public announcement. A buyer reviewing a healthcare platform today may be acquiring a company that already has a sealed relator complaint on file. The absence of a public docket entry does not confirm the absence of a pending complaint.
The Mechanism Regulators Alleged
DOJ alleged that kickbacks generated prescriptions for expensive compounded creams and vitamins regardless of patient need. The public sources state that DOJ alleged RLH managed PCA and funded commission payments.
That alleged mechanism is worth unpacking in detail because it defines the diligence testing path. The chain has three links, and each link corresponds to a specific set of documents a buyer should request.
Link one: demand generation through paid referrals. The alleged scheme started with marketing, not with clinical need. Prescriptions were allegedly generated through a commission-based referral channel rather than through independent clinical judgment. In a compounding pharmacy context, that means the prescriber relationship, the patient contact, and the product selection were all allegedly downstream of a paid referral arrangement. The clinical encounter, if it occurred at all, was allegedly a formality that followed a commercial transaction rather than a medical assessment that preceded it.
That inversion of the normal clinical sequence is the core Anti-Kickback Statute problem. The statute prohibits offering, paying, soliciting, or receiving remuneration to induce or reward referrals of items or services covered by federal healthcare programs. When a commission payment precedes and causes a prescription, the payment is alleged to be remuneration intended to induce a referral, regardless of whether the product prescribed was clinically appropriate for some patients in some circumstances.
Link two: federal program billing. The platform served TRICARE beneficiaries. TRICARE is the federal healthcare program for military members, retirees, and their families, administered by the Defense Health Agency. Billing TRICARE for claims generated through kickbacks implicates the False Claims Act because TRICARE is a federal program, and a claim submitted in violation of the Anti-Kickback Statute is treated as a false claim under the FCA. The government does not need to prove that each individual claim was for a product the patient did not need. It needs to show that the claim was tainted by a kickback arrangement.
That legal structure means the exposure is not limited to claims that were clinically unjustified in isolation. Every claim generated through the allegedly improper referral channel is potentially a false claim, even if some of those claims would have been submitted anyway on clinical grounds. That is why demand-source analysis is a distinct diligence workstream from medical necessity review.
Link three: investor involvement in the referral economics. DOJ alleged that RLH managed PCA and funded the commission payments. That allegation is the element that distinguishes this case from a standard portfolio-company compliance failure. The investor was not alleged to have been a passive capital provider who happened to own a company that misbehaved. The investor was alleged to have been operationally involved in the economics that drove the allegedly improper claims.
The significance of that allegation for buyers is direct. If a PE sponsor’s board approvals, budget decisions, or funding flows are alleged to have supported the referral payment structure, the sponsor’s own records become relevant to the government’s theory. A buyer acquiring a platform from a PE sponsor inherits the portfolio company’s compliance history. It does not automatically inherit the sponsor’s liability, but it does need to understand what the sponsor’s records show about the sponsor’s role in the conduct period.
Warning Signs for Buyers
The following patterns, individually or in combination, should trigger deeper diligence in any healthcare platform with federal program revenue. They are drawn directly from the alleged mechanism in this case and from the public record of how similar FCA matters have developed.
Revenue concentration in federal programs that grows faster than the clinical census. TRICARE, Medicare, and Medicaid revenue that outpaces patient volume growth is a flag. In a compounding pharmacy or specialty pharmacy context, rapid federal program revenue growth warrants a demand-source analysis before closing. The question is not whether the revenue is real. The question is where it came from.
Commission-based or volume-linked marketing contracts. Marketing vendors paid per prescription, per patient, per referral, or on a success-fee basis create Anti-Kickback Statute exposure when the referred services are billed to federal programs. The contract structure alone is not dispositive, but it requires a legal opinion and a compliance review, not just a revenue model review. A marketing contract that is structured as a flat-fee arrangement but that in practice pays more when referral volume increases is functionally a volume-linked arrangement regardless of its label.
Expensive products with weak medical necessity documentation. Compounded creams and specialty vitamins at high price points are a known audit target for TRICARE and CMS. If the product mix is expensive and the prescriber documentation is thin, the claim file will not survive a government audit or a qui tam relator’s review. A diligence sample of claim files should include the most expensive products in the formulary, not a random draw from the full claim population.
Sales-driven prescription initiation. If the sales team or marketing vendor is initiating patient contact before a prescriber has identified a clinical need, the demand-generation model is inverted. Clinical need should precede marketing contact, not follow it. Interview the sales team and the compliance team separately. If their descriptions of the patient acquisition process differ materially, that gap is a diligence finding.
Board or investor approval of referral payments without documented compliance analysis. If board minutes show approval of marketing budgets that include per-referral or per-prescription payments, and the minutes do not reflect a compliance review or legal opinion, that gap is a diligence finding. The absence of a compliance discussion in the board record is not evidence that the compliance discussion happened informally. It is evidence that the board did not treat the referral payment structure as a compliance question.
Monthly financials that show referral payments the compliance files do not explain. A reconciliation between the financial statements and the compliance program is a basic diligence step that is frequently skipped. If the financials show payments to marketing vendors that the compliance files do not address, the gap needs an explanation before closing. The explanation should come from the compliance officer, not from the CFO.
Sealed docket risk. FCA qui tam cases are filed under seal. A buyer cannot search PACER and confirm the absence of a pending relator complaint. The only partial mitigation is a representation and warranty from the seller, combined with escrow or indemnity coverage, and a thorough review of any government subpoenas, civil investigative demands, or audit requests the company has received. Ask specifically whether any government agency has contacted the company about its billing practices, marketing arrangements, or referral relationships in the past five years.
Rapid headcount growth in the sales and marketing function relative to clinical staff. A compounding pharmacy or specialty pharmacy that is growing its sales force faster than its clinical and compliance staff is signaling where it believes revenue comes from. That ratio is a quick screen that does not require access to the compliance files.
How to Read the Primary Source Document
The DOJ press release for the Patient Care America settlement is the primary public source. It is a short document, but it contains several elements that a careful reader should parse before drawing conclusions or citing the case in a diligence memo.
Who are the named settling parties? The release names the pharmacy, two executives, and the PE firm. That list tells you the government’s theory of who was responsible. In a standard portfolio-company FCA case, the PE firm would not typically be named. Its presence here signals that the government’s theory extended to the investor level and that the government had sufficient factual support to include the investor in the settlement rather than limiting the resolution to the operating entity and its direct employees.
What conduct is described? The release describes kickbacks generating prescriptions regardless of patient need. That description maps directly to the Anti-Kickback Statute’s prohibition on remuneration intended to induce referrals of federal program business. The release does not describe a billing-code error or a documentation deficiency. It describes a demand-generation model that was allegedly built around paid referrals.
What program was affected? TRICARE. That matters because TRICARE has its own enforcement infrastructure and audit capacity separate from CMS. The Defense Health Agency and the Defense Criminal Investigative Service have independent authority to investigate and refer TRICARE fraud. A platform with TRICARE concentration faces a different audit profile than a platform with only commercial payer revenue, and the enforcement posture of TRICARE-focused investigations has historically been aggressive in the compounding pharmacy space.
What is the settlement amount and how is it allocated? The total is \$21.36 million across the pharmacy, executives, and PE firm. The public release does not break out the individual allocation in detail. The fact that the PE firm is a named settling party means some portion of the settlement was attributed to the investor. A buyer or investor reading this case for diligence purposes should treat the total as a reference point for the scale of exposure that referral-economics issues can generate in a TRICARE-billing context.
What is not in the release? The release does not describe the CIA terms, if any, or the ongoing compliance obligations. A buyer acquiring a successor entity or a related platform should check the HHS-OIG CIA database separately to determine whether any corporate integrity agreement was entered as part of the resolution. A CIA imposes ongoing monitoring, reporting, and compliance obligations that survive the settlement and bind the operating entity going forward.
What does the qui tam origin tell you? The case originated with a relator. That means someone with inside knowledge of the alleged conduct filed a complaint before the government intervened. In practice, relators in healthcare FCA cases are often current or former employees, sales representatives, or compliance staff. Their complaints typically contain detailed factual allegations drawn from internal documents, emails, and financial records. The existence of a relator complaint means the government had access to internal documents before the settlement was reached.
Diligence Tests Before Signing or Before the Wire
The following tests are specific to the alleged mechanism in this case. They address the exact failure mode the public record describes. They are not a substitute for a full FCA diligence workstream, but they are the tests that the Patient Care America fact pattern makes non-negotiable.
Marketing vendor reconciliation. Pull every marketing contract for the past five years. Map each vendor to its compensation structure, the referral volume it generated, the federal program claims that followed those referrals, and the total payments made. If the vendor was paid on a per-referral or per-prescription basis and the downstream claims went to TRICARE, Medicare, or Medicaid, the contract requires legal review before closing. Do not accept a summary from the seller. Request the underlying contracts and the payment records.
Commission payment trace. Identify every payment that could be characterized as a commission, success fee, patient-acquisition payment, or referral fee. Trace each payment to the approving authority. If investor-level approvals appear in the approval chain, document that finding and assess its significance with healthcare regulatory counsel. The trace should go back to the beginning of the conduct period, not just the most recent fiscal year.
Federal program revenue demand-source analysis. For each federal program revenue line, identify the demand source. Was the patient referred by a treating physician based on clinical need? Was the patient contacted by a marketing vendor? Was the prescription initiated by a sales representative? The answer determines whether the claim has a defensible medical necessity foundation and whether the referral arrangement that generated the claim was structured in a way that creates AKS exposure.
Medical necessity sample review. Pull a statistically meaningful sample of claims for expensive products. For each claim, confirm that the prescriber had an independent clinical relationship with the patient, that the prescription was supported by documented clinical need, and that the claim file would survive a government audit. Weight the sample toward the highest-cost products and the highest-volume prescribers. If the sample shows thin documentation, engage a healthcare regulatory attorney to estimate the population-level exposure before closing.
Investor record review. Request board minutes, budget approvals, investor committee materials, and monthly financial reports for the period covered by the alleged conduct. Look for any reference to marketing payments, commission structures, referral economics, or federal program revenue growth. If investor records show awareness of or involvement in the referral payment structure, assess whether that awareness creates successor liability or indemnity exposure. This step is frequently omitted in PE-backed healthcare platform diligence. It should not be.
Prescriber concentration analysis. Identify the top twenty prescribers by claim volume. For each, determine whether the prescriber had an independent clinical relationship with the patients whose claims were submitted, whether the prescriber received any payments, meals, samples, or other remuneration from the company or its marketing vendors, and whether the prescriber’s volume is consistent with the size and specialty of their practice. Outlier prescribers are a known audit trigger and a relator target.
Whistleblower and government contact review. Ask the seller to represent and warrant that no qui tam complaint has been filed, no civil investigative demand has been received, no government subpoena is pending, and no government audit is in progress. Require disclosure of any prior government contact related to billing, marketing, or referral practices. Back the representation with escrow or indemnity coverage sized to the potential exposure. Ask specifically about any contact from the Defense Criminal Investigative Service, the HHS-OIG, or the DOJ Civil Division.
CIA and exclusion database check. Search the HHS-OIG CIA database and the OIG exclusion database for the company, its executives, its key marketing vendors, and its highest-volume prescribers. An excluded party cannot bill federal programs, and a company under a CIA has ongoing compliance obligations that a buyer inherits. A CIA also typically requires the company to maintain a compliance officer, a compliance committee, and a hotline, and to submit annual reports to the OIG. Confirm that those obligations are being met if a CIA is in place.
Indemnity and escrow sizing. FCA exposure in a federal program revenue context can be significant. The False Claims Act provides for treble damages plus per-claim civil monetary penalties. A \$21.36 million settlement on a compounding pharmacy platform is a reference point, not a ceiling. Escrow and indemnity coverage should be sized to the estimated exposure under a treble-damages analysis, not to a round number that feels commercially comfortable. Engage healthcare regulatory counsel to estimate the exposure range before the escrow negotiation begins.
By the Numbers
| Data Point | Public Source Fact | Buyer Diligence Meaning |
|---|---|---|
| Settlement announcement date | September 18, 2019 | Older conduct remains a current diligence model; FCA cases can take years from relator filing to public announcement, meaning sealed risk exists in any active platform. |
| Total settlement amount | \$21.36 million across pharmacy, executives, and PE firm | Referral-generation issues can create material claim exposure; the PE firm was a named settling party, not a bystander. |
| Federal program affected | Platform served TRICARE beneficiaries | Federal program concentration requires heightened billing, AKS, and demand-source testing; TRICARE has independent enforcement infrastructure separate from CMS. |
| Alleged mechanism | DOJ alleged kickbacks generated prescriptions regardless of patient need | Medical necessity and marketing economics must be tested together in the same diligence workstream, not in separate tracks. |
| Investor allegation | DOJ alleged RLH managed PCA and funded commission payments | Sponsor operational involvement can extend FCA exposure to the investor level; investor records are diligence documents. |
| Case origin | Qui tam relator action under the False Claims Act | Sealed relator complaints may exist for any healthcare platform; seller representations and escrow are partial mitigants, not complete protection. |
| Compliance gap indicator | Commission payments allegedly funded by investor without documented compliance review | Board minutes and budget approvals are diligence documents, not just governance records; their absence or silence on referral economics is itself a finding. |
| Prescriber relationship risk | Prescriptions allegedly generated through paid referral channel rather than independent clinical judgment | Prescriber concentration analysis and independent clinical relationship verification are required steps, not optional enhancements. |
Source footer: Figures and posture are drawn from the DOJ primary source listed below. No additional enforcement facts, dollar amounts, or dates have been introduced.
Buyer and Investor Takeaway
Do not treat marketing contracts as ordinary growth spend in a healthcare platform with federal program revenue. In TRICARE, Medicare, and Medicaid billing contexts, the source of demand can be as legally significant as the revenue itself. A platform that generates federal program revenue through paid referrals rather than through independent clinical demand has a different risk profile than its revenue line suggests.
A buyer needs to know who was paid, why they were paid, whether the payment was tied to federal program volume, and whether the claims that followed were medically necessary and generated through a compliant referral process. Those are not compliance department questions to be answered after closing. They are transaction questions that belong in the diligence workstream before the letter of intent is signed, because the answers affect valuation, escrow sizing, and the decision whether to proceed at all.
The Patient Care America case adds a second layer that most healthcare platform diligence does not adequately address: the investor’s own records. If the PE firm’s board minutes, budget approvals, or monthly financial reports show awareness of or involvement in the referral payment structure, those records are potentially relevant to the government’s theory of liability. A buyer acquiring a platform from a PE sponsor should request and review those records, not just the portfolio company’s compliance files. The request may be resisted. The resistance is itself informative.
The practical implication is that diligence scope in a PE-backed healthcare platform should include all of the following:
- The portfolio company’s compliance program, policies, training records, and claim files.
- The marketing and referral economics, traced from the vendor contract to the individual claim.
- The investor’s own records of approvals, funding decisions, and financial oversight of the referral payment structure.
- Any government contact, subpoena, civil investigative demand, audit, or sealed docket risk.
- A prescriber concentration and independent clinical relationship analysis for the highest-volume referral sources.
- Indemnity and escrow coverage sized to the estimated FCA exposure under a treble-damages analysis.
The False Claims Act’s qui tam mechanism means that a relator may have already filed a complaint that is sitting under seal. The government may be investigating. The company may not know. The seller may not know. The only partial protection for a buyer is a robust representation and warranty, a thorough diligence process, and escrow coverage that reflects the actual risk profile of the platform rather than the seller’s preferred narrative about its compliance posture.
One additional structural point: the FCA’s statute of limitations can extend to ten years in some circumstances, and the government’s ability to investigate conduct that predates a buyer’s acquisition is not limited by the acquisition itself. A buyer who closes on a platform with unresolved referral-economics risk does not start with a clean slate. It starts with whatever the seller’s conduct history has created, and it owns that history from the moment the wire clears.
SPP Bottom Line
Patient Care America is a clean diligence warning with a specific and testable thesis: when referral economics, medical necessity, and investor approvals converge in a federal healthcare program billing context, buyer-side diligence has to follow the money all the way into the claim file and all the way up into the investor’s own records.
The \$21.36 million settlement is not the point. The point is the alleged mechanism: commissions funded by the investor, prescriptions generated regardless of clinical need, claims billed to a federal program. Each link in that chain is a diligence test. A buyer who does not run those tests before closing is accepting risk that the seller has already priced into the deal, or that neither party has yet quantified.
The broader lesson for PE-backed healthcare platforms is structural. The corporate separation between a fund and its portfolio company does not automatically insulate the investor from FCA exposure if the investor’s conduct is alleged to have touched the billing mechanism. Diligence has to account for that possibility, and transaction documents have to allocate the risk explicitly. A representation that the company has no pending government investigations is not the same as a representation that no qui tam complaint has been filed. Both representations belong in the purchase agreement, and both need to be backed by escrow.
The case is also a reminder that the FCA’s qui tam mechanism creates an asymmetry that favors the government and the relator. A relator with inside knowledge can file a detailed complaint, wait under seal while the government investigates, and surface years after the conduct occurred. A buyer who closes without testing the demand-generation model is betting that no such complaint exists. That is not a diligence posture. It is a risk assumption.